Manejo práctico de ustekinumab en la psoriasis moderada-grave

Notario, J.; Bordas, X.

doi:10.1016/S0001-7310(12)70009-1

Article information

Resumen

Ustekinumab (UST) es hasta la fecha el último fármaco biológico aprobado para el tratamiento de la psoriasis. En su manejo práctico nos son útiles tanto los trabajos con UST como la experiencia previa acumulada con otros agentes. Los estudios previos al tratamiento, así como su monitorización y seguimiento presentan semejanzas entre los diferentes fármacos biológicos. En otros aspectos como el tratamiento combinado o el tránsito entre tratamientos, la todavía corta experiencia con UST nos obliga a tomar decisiones según la práctica seguida con otros agentes biológicos.

El objetivo de este artículo es repasar algunos aspectos relacionados con el manejo práctico de UST incidiendo en características diferenciales del fármaco e intentar aprovechar el conocimiento de que disponemos con otras terapias biológicas para optimizar su uso.

Palabras clave:

Psoriasis

Ustekinumab

Fármacos biológicos

Tratamiento combinado

Tránsito tratamientos

Abstract

Ustekinumab is the latest biologic agent to be approved for the treatment of psoriasis. Experience is therefore limited, but data from studies of ustekinumab can be complemented by experience with other biologic agents. While the guidelines for pretreatment screening and follow-up practices are similar in all of the biologic therapies, no standardized information on combination therapy or treatment switches is yet available for ustekinumab, and dermatologists thus have to base their decisions on experience with other biologic agents.

This chapter discusses several aspects related to the use of ustekinumab in clinical practice. We focus on the distinguishing characteristics of this drug and discuss how our knowledge and experience with other biologic agents can be used to help optimize the use of ustekinumab.

Keywords:

Psoriasis

Ustekinumab

Biologic agents

Combination therapy

Treatment switch

Full text is only aviable in PDF

Bibliografía

[1.]

Ficha técnica de ustekinumab. (Consultado 16/07/2011). Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf.

[2.]

Disponible en: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125261lbl.pdf.

[3.]

J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, W. Kirch.

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

Br J Dermatol, 159 (2008), pp. 513-526

http://dx.doi.org/10.1111/j.1365-2133.2008.08732.x | Medline

[4.]

L. Puig, E. Daudén, J.M. Carrascosa.

Comentarios a las directrices europeas y británicas sobre el tratamiento de la psoriasis.

Actas Dermosifiliogr, 101 (2010), pp. 285-290

Medline

[5.]

L. Puig, X. Bordas, J.M. Carrascosa, E. Daudén, C. Ferrándiz, J.M. Hernanz, et al.

Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr, 100 (2009), pp. 277-286

Medline

[6.]

C.H. Smith, A.V. Anstey, J.N. Barker, A.D. Burden, R.J. Chalmers, D.A. Chandler, et al.

(Chair of Guideline Group). British Association of Dermatologists’ guidelines for biologics interventions for psoriasis 2009.

Br J Dermatol, 161 (2009), pp. 987-1019

http://dx.doi.org/10.1111/j.1365-2133.2009.09505.x | Medline

[7.]

National electronic Library for Medicines. Usketinumab. (Consultado 17/07/2011). Disponible en: http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/ustekinumab/.

[8.]

L. Clark, M. Lebwohl.

The effect of weight on the efficacy of biologic therapy in patients with psoriasis.

J Am Acad Dermatol, 58 (2008), pp. 443-446

http://dx.doi.org/10.1016/j.jaad.2007.11.011 | Medline

[9.]

M. Lebwohl, N. Yeilding, P. Szapary, Y. Wang, S. Li, Y. Zhu, et al.

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

J Am Acad Dermatol, 63 (2010), pp. 571-579

http://dx.doi.org/10.1016/j.jaad.2009.11.012 | Medline

[10.]

C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang, et al.

PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1).

Lancet, 371 (2008), pp. 1665-1674

http://dx.doi.org/10.1016/S0140-6736(08)60725-4 | Medline

[11.]

K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, et al.

PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2).

Lancet, 371 (2008), pp. 1675-1684

http://dx.doi.org/10.1016/S0140-6736(08)60726-6 | Medline

[12.]

Leonardi C, Sofen H, Yeilding N, Li S, Menter A. Maintenance of Long-term Efficacy of ustekinumab Through Year 3 for Patients with Moderate-to-severe Psoriasis. Poster (P589) presented at: 19th Congress of the European Academy of Dermatology and Venereology. Gotemburgo, 6–10 Oct 2010.

[13.]

J.M. Carrascosa.

Estrategias para optimizar el tratamiento con efalizumab.

Actas Dermosifiliogr, 99 (2008), pp. 37-50

Medline

[14.]

Paul C, Puig L, Luger T, Lambert J, Chimenti S, Girolomoni G, et al. Ustekinumab is well-tolerated & effective in patients with psoriasis inadequately responsive to methotrexate: Week 12 results from the TRANSIT study. Aceptado como póster. XX Congreso AEDV. Lisboa, Oct 2011.

[15.]

A.M. Downs.

Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.

Br J Dermatol, 163 (2010), pp. 433-434

http://dx.doi.org/10.1111/j.1365-2133.2010.09832.x | Medline

[16.]

Q.U. Kamili, A. Miner, A. Hapa, A. Menter.

Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.

J Drugs Dermatol, 10 (2011), pp. 539-544

Medline

[17.]

R.J. Driessen, P.C. Van de Kerkhof, E.M. De Jong.

Etanercept combined with methotrexate for high-need psoriasis.

Br J Dermatol, 159 (2008), pp. 460-463

http://dx.doi.org/10.1111/j.1365-2133.2008.08669.x | Medline

[18.]

C. Zachariae, N.J. Mørk, T. Reunala, H. Lorentzen, E. Falk, S.L. Karvonen, et al.

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

Acta Derm Venereol, 88 (2008), pp. 495-501

http://dx.doi.org/10.2340/00015555-0511 | Medline

[19.]

L. Kircik, J. Bagel, N. Korman, A. Menter, C.A. Elmets, J. Koo, Unite Study Group, et al.

Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.

J Drugs Dermatol, 7 (2008), pp. 245-253

Medline

[20.]

P. Gisondi, M. Del Giglio, C. Cotena, G. Girolomoni.

Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigatorblinded pilot trial.

Br J Dermatol, 158 (2008), pp. 1345-1349

http://dx.doi.org/10.1111/j.1365-2133.2008.08564.x | Medline

[21.]

E.C. Smith, C. Riddle, M.A. Menter, M. Lebwohl.

Combining systemic retinoids with biologic agents for moderate to severe psoriasis.

Int J Dermatol, 47 (2008), pp. 514-518

http://dx.doi.org/10.1111/j.1365-4632.2008.03470.x | Medline

[22.]

A. Gottlieb, A. Menter, A. Mendelsohn, Y.K. Shen, S. Li, C. Guzzo, et al.

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial.

Lancet, 373 (2009), pp. 633-640

http://dx.doi.org/10.1016/S0140-6736(09)60140-9 | Medline

[23.]

W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, S. Katz, Ustekinumab Crohn's Disease Study Group, et al.

A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

Gastroenterology, 135 (2008), pp. 1130-1141

http://dx.doi.org/10.1053/j.gastro.2008.07.014 | Medline

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter